Arxx Therapeutics

Arxx Therapeutics AS aims to bring to market the first disease-modifying treatment for systemic sclerosis. 

The company aims to advance a novel antifibrotic therapy to modify disease progression, and in some cases, potentially reverse the fibrotic damage to tissue. The therapeutic approach also holds promise as a therapeutic in specific cancers which currently are resistant to conventional as well as immunemodulating anticancer treatments.

Latest news about Arxx Therapeutics

  • Wed May 05 2021

    Arxx Therapeutics secures NOK110

    APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Inv

    Read full article